216 related articles for article (PubMed ID: 9215817)
21. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Goss PE; Winer EP; Tannock IF; Schwartz LH
J Clin Oncol; 1999 Jan; 17(1):52-63. PubMed ID: 10458218
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
[TBL] [Abstract][Full Text] [Related]
23. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.
Gill PG; Gebski V; Snyder R; Burns I; Levi J; Byrne M; Coates A
Ann Oncol; 1993 Nov; 4(9):741-4. PubMed ID: 8280654
[TBL] [Abstract][Full Text] [Related]
25. Aminoglutethimide as second line therapy in advanced breast cancer.
Elomaa I; Blomqvist C; Rissanen P
Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
[TBL] [Abstract][Full Text] [Related]
27. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
28. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Gershanovich M; Chaudri HA; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichardt P; O'Higgins N; Romieu G; Friederich P; Lassus M
Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
[TBL] [Abstract][Full Text] [Related]
29. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
30. Sequential hormone therapy for advanced breast cancer.
Von Roenn JH; Bonomi PD; Gale M; Anderson KM; Wolter JM; Economou SG
Semin Oncol; 1988 Apr; 15(2 Suppl 1):38-43. PubMed ID: 3368799
[TBL] [Abstract][Full Text] [Related]
31. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
32. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
33. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.
Abrams J; Aisner J; Cirrincione C; Berry DA; Muss HB; Cooper MR; Henderson IC; Panasci L; Kirshner J; Ellerton J; Norton L
J Clin Oncol; 1999 Jan; 17(1):64-73. PubMed ID: 10458219
[TBL] [Abstract][Full Text] [Related]
34. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.
Kakolyris S; Samonis G; Koukourakis M; Vlachonicolis J; Kalbakis K; Agelaki S; Chalkiadakis G; Sanidas E; Tsiftsis D; Georgoulias V
Am J Clin Oncol; 1999 Jun; 22(3):273-7. PubMed ID: 10362335
[TBL] [Abstract][Full Text] [Related]
35. Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Lundgren S; Gundersen S; Klepp R; Lønning PE; Lund E; Kvinnsland S
Breast Cancer Res Treat; 1989 Nov; 14(2):201-6. PubMed ID: 2690972
[TBL] [Abstract][Full Text] [Related]
36. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.
Paterson AH; Hanson J; Pritchard KI; Sansregret E; Dahrouge S; McDermot RS; Fine S; White DF; Trudeau M; Stewart DJ
Semin Oncol; 1990 Dec; 17(6 Suppl 9):52-62. PubMed ID: 2259927
[TBL] [Abstract][Full Text] [Related]
37. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
38. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
39. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).
Muss HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Stuart JJ; Richards F
Semin Oncol; 1985 Mar; 12(1 Suppl 1):55-61. PubMed ID: 3883503
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]